$CYAB

CYABRA, INC. (CYAB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Adoption of an amendment to the 2026 Omnibus Equity Incentive Plan On September 2, 2026, Cyabra, Inc. (the “ Company ”) hel

U.S. stocks were mixed on Friday, with the Dow up 0.19% and the NASDAQ down 0.01%. The Chicago PMI fell to 47.1 in August, missing estimates. Quoin Pharmaceuticals (QNRX) rose 43% after positive clinical trial results and financing news. BioXcel Therapeutics (BTAI) dropped 73% after filing for bankruptcy.

Cyabra, Inc. (Nasdaq: CYAB) reported record Q2 2026 revenue of $1.9 million, up 39% year over year from $1.3 million, driven mainly by new customer wins and higher existing-customer revenue. Gross margin stayed about 84%. The company also cited a $500,000+ research institute agreement, new government and intelligence customers, and a $6.0 million private placement.

Brahmy Dan (Chief Executive Officer) purchased 53,650 shares of CYABRA, INC. (CYAB) at $0.44 on 2026-07-10.

CYABRA, INC. (CYAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 7 ea029760001ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 9, 2026, between Cyabra, Inc., a Delaware corporation (the “ Company ”), and each purchaser

Cyabra, Inc. (Nasdaq: CYAB) priced a $6.0 million private placement to sell 13,818,770 shares plus Series A and Series B warrants at $0.435 per share. Series A warrants exercise at $0.50 and expire five years; Series B exercise at $0.45 and expire 12 months, both subject to stockholder approval. Preferred shares will convert to common or equivalents, pending approval.